Read More Pharma Industry News Why pediatric ependymoma inclusion may be the bigger strategic signal for Plus Therapeutics Why pediatric ependymoma may be the bigger strategic signal for Plus Therapeutics and what it means for REYOBIQ’s 2026 growth roadmap. Read more. bySoujanya RaviApril 11, 2026